0001209191-21-018152.txt : 20210305 0001209191-21-018152.hdr.sgml : 20210305 20210305153015 ACCESSION NUMBER: 0001209191-21-018152 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210303 FILED AS OF DATE: 20210305 DATE AS OF CHANGE: 20210305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ASADORIAN RAFFI CENTRAL INDEX KEY: 0001628970 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35068 FILM NUMBER: 21718241 MAIL ADDRESS: STREET 1: C/O ACELRX PHARMACEUTICALS, INC. STREET 2: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 351 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-03 0 0001427925 ACELRX PHARMACEUTICALS INC ACRX 0001628970 ASADORIAN RAFFI C/O ACELRX PHARMACEUTICALS, INC. 351 GALVESTON DRIVE REDWOOD CITY CA 94063 0 1 0 0 Chief Financial Officer Common Stock 2021-03-03 4 A 0 68750 0.00 A 260597 D Stock Option (Right to Buy) 1.88 2021-03-03 4 A 0 137500 0.00 A 2031-03-03 Common Stock 137500 137500 D Stock Option (Right to Buy) 1.88 2021-03-03 4 A 0 68750 0.00 A 2031-03-03 Common Stock 68750 68750 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest in three equal consecutive annual installments on March 3, 2022, March 3, 2023 and March 3, 2024. Balance includes acquisition of 8,548 shares of Common Stock through the Company's Employee Stock Purchase Plan. The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the date of grant and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. On March 3, 2021, the Reporting Person was granted performance options subject to the satisfaction of share price targets over a performance period from March 3, 2021 to December 31, 2024 (the "Performance Period"), as determined by the Compensation Committee (the "Committee") of the Company's Board of Directors. The performance options shall be earned as follows: (i) 33% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $4.00, (ii) an additional 33% of the performance option if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $5.00, and (iii) 34% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $6.00. Once earned, the performance options will vest on the one-year anniversary of the date on which the Committee certified achievement of an applicable price target, so long as the reporting person remains in continuous service through such applicable vesting date. /s/ Martha Adler, Attorney-In-Fact 2021-03-05